Transcript-Savvy Discovery Is a Smart Bet
Drug Developers Are Finding Ways to Bend the Transcriptome to Their Will
Humanizing Animals for Immuno-Oncology
Success in Humanizing Mice Has Inspired Similar Efforts in Rats, Pigs, and Other Animals
Molecular Dx Has Your (Copy) Number
CNV Detection and Analysis Tools Are Being Used To Fill Genetic Diagnostic Gaps
Probiotics Help Save the Spine
Sounds of Science Podcast
Nanobiotech in the U.S.
FDA’s recently enacted budget for this fiscal year included some good news for proponents of nanotechnology as well as the promise for more in the years ahead. The agency’s National Center for Toxicological Research (NCTR), which conducts research on new medical products like nanomaterials, was approved $60 million for fiscal 2012, flat compared to FY ’11. Sen. Mark Pryor (D-AR) also inserted language in the House-Senate conference report endorsing the development of a nanotechnology core facility. One such site became operational last fiscal year, the other is set for FY 2012. These are among efforts to maintain U.S. leadership in nanotech. Europe is the nearest-term threat, but China, Singapore, and Taiwan are among others. What are your predictions?